Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipid nanoparticles engineered to target therapeutic RNA to the pancreas.

Nature·2026
Same author

The RNA delivery dilemma-lipid versus polymer nanoparticle platforms.

Drug delivery and translational research·2026
Same author

A symphony of immunity: How HPV mRNA-LNP vaccination orchestrates systemic anti-tumor responses.

Molecular therapy. Nucleic acids·2026
Same author

cSMRTS for cancer therapeutics.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

On The Retrograde Transport of RNA-Loaded Lipid Nanoparticles Designed for Brain Delivery.

ACS nanoscience Au·2025
Same author

The impact of chemical reactivity on the quality and stability of RNA-LNP pharmaceuticals.

Nature reviews. Chemistry·2025

Related Experiment Video

Updated: May 18, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

RNAi-based nanomedicines for targeted personalized therapy.

Ala Daka1, Dan Peer

  • 1Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S. Wise Faculty of Life Science, Israel.

Advanced Drug Delivery Reviews
|September 15, 2012
PubMed
Summary

RNA interference (RNAi) therapeutics show promise but face delivery challenges. New targeted nanostrategies combined with "omics" data aim to improve RNAi payload delivery for personalized medicine.

More Related Videos

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Related Experiment Videos

Last Updated: May 18, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Area of Science:

  • Biotechnology and Nanomedicine
  • Molecular Biology and Genetics
  • Personalized Medicine

Background:

  • RNA interference (RNAi) is advancing towards clinical applications, demonstrating therapeutic potential.
  • Efficient and specific delivery of RNAi payloads to target cells remains a significant hurdle for clinical success.
  • Current delivery methods lack the precision required for safe, potent, and personalized RNAi therapeutics.

Purpose of the Study:

  • To review and introduce progress in designing targeted nanostrategies for RNAi delivery.
  • To explore the integration of "omics" disciplines for personalizing RNAi-based therapeutics.
  • To address the challenges hindering the clinical approval and widespread use of RNAi technology.

Main Methods:

  • Evaluation of recent studies focusing on nano-scaled delivery systems for RNAi.
  • Analysis of targeted strategies designed to enhance cellular specificity and payload delivery.
  • Integration of 'omics' data for tailoring RNAi therapeutics to individual patients.

Main Results:

  • Identified promising targeted nanostrategies that show potential to overcome current delivery limitations.
  • Highlighted the synergy between nanodelivery systems and 'omics' approaches for personalized RNAi.
  • Demonstrated the feasibility of developing more specific and potent RNAi therapeutic delivery systems.

Conclusions:

  • Targeted nanostrategies are crucial for advancing RNAi therapeutics beyond clinical trials.
  • The combination of nanotechnology and 'omics' offers a pathway to personalized and effective RNAi treatments.
  • Continued research in targeted delivery is essential for realizing the full clinical potential of RNAi.